<DOC>
	<DOC>NCT00680186</DOC>
	<brief_summary>The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic VTE. The primary objective is to investigate the efficacy of dabigatran compared to warfarin during the 6 month treatment period. The investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.</brief_summary>
	<brief_title>Phase III Study Testing Efficacy &amp; Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criteria: Acute symptomatic uni or bilateral Deep Vein Thrombosis (DVT) of the leg involving proximal veins, and/or Pulmonary Embolism (PE) Male or female, being 18 years of age or older Written informed consent for study participation Exclusion criteria: Persistent symptoms of VTE PE requiring urgent intervention Use of vena cava filter Contraindications to anticoagulant therapy Allergy to study medications Elevated Aspartateaminotransferase (AST) or Alanineaminotransferase (ALT) &gt; 3x Upper Limit of Normal (ULN) or known liver disease expected to have an impact on survival Severe renal impairment Patients considered unsuitable for inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>